Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Japanese Encephalitis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Japanese Encephalitis - Pipeline Review, H1 2016', provides an overview of the Japanese Encephalitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Japanese Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Japanese Encephalitis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Japanese Encephalitis - The report reviews pipeline therapeutics for Japanese Encephalitis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Japanese Encephalitis therapeutics and enlists all their major and minor projects - The report assesses Japanese Encephalitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Japanese Encephalitis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Japanese Encephalitis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Japanese Encephalitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Japanese Encephalitis Overview 6 Therapeutics Development 7 Pipeline Products for Japanese Encephalitis - Overview 7 Pipeline Products for Japanese Encephalitis - Comparative Analysis 8 Japanese Encephalitis - Therapeutics under Development by Companies 9 Japanese Encephalitis - Therapeutics under Investigation by Universities/Institutes 10 Japanese Encephalitis - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Japanese Encephalitis - Products under Development by Companies 14 Japanese Encephalitis - Products under Investigation by Universities/Institutes 15 Japanese Encephalitis - Companies Involved in Therapeutics Development 16 Indian Immunologicals Limited 16 Kineta, Inc. 17 Panacea Biotec Limited 18 Vaxine Pty Ltd 19 Zydus Cadila Healthcare Limited 20 Japanese Encephalitis - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 23 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 FDX-000 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Japanese encephalitis vaccine - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Japanese encephalitis vaccine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Japanese encephalitis vaccine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Japanese encephalitis vaccine - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Japanese encephalitis vaccine - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Japanese encephalitis vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Japanese encephalitis vaccine - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Japanese encephalitis vaccine - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Japanese encephalitis vaccine - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Agonize IRF-3 for Viral Infections - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Japanese Encephalitis - Dormant Projects 40 Japanese Encephalitis - Discontinued Products 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables
Number of Products under Development for Japanese Encephalitis, H1 2016 7 Number of Products under Development for Japanese Encephalitis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Comparative Analysis by Unknown Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Japanese Encephalitis - Pipeline by Indian Immunologicals Limited, H1 2016 16 Japanese Encephalitis - Pipeline by Kineta, Inc., H1 2016 17 Japanese Encephalitis - Pipeline by Panacea Biotec Limited, H1 2016 18 Japanese Encephalitis - Pipeline by Vaxine Pty Ltd, H1 2016 19 Japanese Encephalitis - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 20 Assessment by Monotherapy Products, H1 2016 21 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Japanese Encephalitis - Dormant Projects, H1 2016 40 Japanese Encephalitis - Discontinued Products, H1 2016 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
